Dominican Republic vs United Kingdom: The number of people with susceptibility test result for rifampicin
Dominican Republic
1,724
in 2021
United Kingdom
1,734
in 2021
Dominican Republic rank
55th
United Kingdom rank
54th
The number of people with susceptibility test result for rifampicin over time
- Dominican Republic
- United Kingdom
How they compare
United Kingdom currently reports 1,734 against 1,724 in Dominican Republic, a difference of 10.
Across all 5 years both countries report, United Kingdom has been ahead every year.
Dominican Republic ranks 55th and United Kingdom ranks 54th of 155 countries.
United Kingdom has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Dominican Republic | United Kingdom | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 540.33 | 1,947 | 1,407 | United Kingdom |
| 2020s | 1,406 | 1,640 | 233.5 | United Kingdom |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Dominican Republic or United Kingdom?
- United Kingdom, at 1,734 against 1,724 in Dominican Republic as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Dominican Republic and United Kingdom?
- 10, with United Kingdom ahead.
- How many years of comparable data are there for Dominican Republic and United Kingdom?
- 5 years are reported by both, from 2017 to 2021.
- How do Dominican Republic and United Kingdom rank globally for the number of people with susceptibility test result for rifampicin?
- Dominican Republic ranks 55th and United Kingdom ranks 54th of 155 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients.. Statizoid refreshes it automatically from the source and publishes the full history for both places.